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AUTOIMMUNE	  PANCREATITIS.	  
Distinct	   pathophysiological	   profiles	   for	   discrimination	   of	  
autoimmune	  pancreatitis	  subtypes.	  
	  
Keywords:	  	  Type	  1	  and	  type	  2	  autoimmune	  pancreatitis,	  chronic	  pancreatitis	  and	  pancreatic	  cancer.	  	  	  
	  
Introduction	  :	  Autoimmune	  pancreatitis	  (AIP)	  is	  a	  new	  nosological	  entity	  that	  was	  first	  reported	  by	  Sarles	  et	  al.	  in	  1961(1)	  in	  Marseilles	  and	  then	  named	  by	  Yoshida	  et	  al.	   in	  1995(2)	  in	  Japan.	   	  Many	  Western	  researchers	  then	  ignored	  it,	  but	  over	  the	  last	  decade,	   interest	  in	  AIP	  has	  grown,	  its	  recognition	  has	  increased	  and	  the	  disease	  has	  been	  intensively	  studied	  around	  the	  world.	  AIP	   is	   an	   immune	   mediated	   fibro-­‐inflammatory	   form	   of	   pancreatitis	   that	   has	   a	   unique	  histopathologic	  pattern:	  a)	  a	  periductal	  lymphoplasmocytic	  infiltration,	  b)	  storiform	  fibrosis	  and	  c)	   obliterative	   phlebitis	   that	  makes	   it	   distinguishable	   from	   other	   pancreas	   disease.	  Moreover,	  clinically	  AIP	  is	  the	  only	  type	  of	  pancreatitis	  that	  responds	  to	  steroid	  administration.	  	  	   	  	  
	   	  
Figure	  1	  :	  Hematoxylin	  and	  eosin	  stain:	  	  
a)	   AIP	   type	  1,	   low	  magnitude,	   cellular	  
fibrosis	   replacing	   periductal	   acinar	  
tissues	   and	   small	   duct	   with	  
lymphoplasmocytic	  infiltration	  	  
b)	   AIP	   type	   2,	   low	   magnitude	   and	   c)	  
intermediary	   magnitude	   showing	  
periductal	   lymphoplasmocytic	  
infiltration	   and	   storiform	   fibrosis	  
characteristic	  to	  AIP	  	  
d)	   AIP	   type	   2,	   high	   magnitude,	  
pancreatic	   duct	   showing	   granulocytic	  
epithelial	   lesions	   (GEL)	   which	   is	   the	  
destruction	   of	   the	   epithelium	   by	  
invading	  granulocytes,	   specific	   to	   type	  
2	  AIP.	  	  
	   	  
	   	   	   2	  
The	   Honolulu	   consensus	   document,	   recently	   published	   by	   Chari	   et	   al.,	   clarifies	   the	  histopathologic	  and	  clinical	  subtypes	  of	  AIP(3).	  It	  appears	  that	  there	  are	  two	  types	  of	  AIP,	  with	  distinct	   clinical	   profiles	   including	   differences	   in	   age	   of	   appearance,	   sex	   ratio,	   geographic	  distribution	  and	  also	  in	  their	  histological	  and	  immunological	  signature	  (table	  1).	  	  Type	   1	   AIP	   (the	   most	   common	   type	   in	   Asia),	   was	   also	   named	   lymphoplasmocytic	   sclerosing	  pancreatitis	  (LPSP)	  because	  of	  its	  histological	  features	  its	  association	  with	  elevated	  IgG4	  serum	  levels	   and	   IgG4	  positive	   cells	   infiltration	   as	  well	   as	   various	  other	   autoantibodies	   such	   as	   anti-­‐nuclear	  antibodies,	  anti-­‐lactoferrin	  and	  anti-­‐carbonic	  anhydrase	  II.	  Furthermore,	  this	  latter	  type	  involves	  other	  organs	  than	  the	  pancreas,	  indicating	  that	  it	  is	  more	  a	  systemic	  disease.	  	  Type	   2	   AIP,	   called	   idiopathic	   duct	   centric	   pancreatitis	   (IDCP),	   is	   recognized	   by	   its	   specific	  histological	   feature:	   granulocytic	   epithelial	   lesions	   (GEL).	   These	   lesions	   consist	   of	   a	   focal	  disruption	   and	   destruction	   of	   the	   duct	   epithelium	   caused	   by	   the	   invasion	   of	   neutrophilic	  granulocytes,	  which	  makes	  some	  people	  call	  it	  AIP	  with	  GEL.	  This	  later	  subtype	  is	  more	  common	  in	  Western	  countries.	  	  	  	   Type	  1	  AIP	   Type	  2	  AIP	  
Clinical	  presentation	   Obstructive	  jaundice	  75%	  Acute	  pancreatitis	  15%	   Obstructive	  jaundice	  17-­‐40%	  Acute	  pancreatitis	  50%	  
Mean	  age	   60	   40	  
Sex	  ratio	   Male>>Female	   Male=Female	  
Geographic	  distribution	   Asia>	  USA	  and	  EU	   EU>USA>Asia	  
Serology	   High	  serum	  IgG/IgG4	  Presence	  of	  autoantibodies	   Normal	  serum	  IgG/IgG4	  No	  autoantibodies	  
Other	  organs	  involvement	  	   1)	  sclerosing	  sialadenitis	  2)	  IgG4+	  associated	  cholangitis	  	  3)	  retroperitoneal	  fibrosis	  4)	   IgG4+	   associated	   tubulo-­‐interstitial	  nephritis	  
1)	  Inflammatory	  bowel	  disease	  	  
	  
Table	  1:	  Main	  differences	  between	  AIP	  subtypes.	  	  Because	   the	   main	   differential	   diagnosis	   of	   AIP	   is	   pancreatic	   cancer,	   it	   is	   important	   to	  differentiate	   them	   before	   surgery.	   Although	   it	   would	   be	   detrimental	   to	   treat	   a	   patient	  with	   a	  resectable	  pancreatic	  carcinoma	  with	  steroid,	  an	  unnecessary	  surgery	  in	  AIP	  patients	  should	  be	  avoided.	  Furthermore,	  the	  awareness	  that	  AIP	  may	  be	  part	  of	  a	  new	  clinicopathological	  entity	  of	  an	  IgG4-­‐related	   disease,	   together	   with	   retroperitoneal	   fibrosis,	   sclerosing	   sialadenitis	   and	   sclerosing	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cholangitis	  has	   recently	  progressed(4).	  This	  entity	  may	  also	   incorporate	  pulmonary,	   renal	  and	  other	  extrapancreatic	  sites	  and	  is	  only	  linked	  with	  type	  I	  AIP.	  	  	  However,	   the	   etiology	   and	   the	   pathophysiological	   mechanisms	   of	   AIP	   remain	   still	   unknown.	  Several	  findings	  suggest	  that	  an	  autoimmune	  mechanism	  might	  be	  involved.	  Mainly	  because	  AIP	  is	  associated	  with	  1)	  hypergammaglobulinemia	  and	  2)	  increased	  levels	  of	  IgG4	  in	  type	  I	  AIP,	  but	  also	  because	  of	  3)	  the	  presence	  of	  a	  particular	  common	  human	  leukocyte	  antigen	  (HLA)	  in	  some	  populations,	   4)	   high	   titers	   of	   circulating	   immune	   complexes,	   and	   of	   an	   elevated	   number	   of	  regulatory	   T	   (Tregs)	   cells	   in	   tissue	   and	   blood	   of	   affected	   individuals,	   and	   5)	   the	   presence	   of	  autoantibodies	   such	   as	   anti-­‐nuclear	   antibodies	   (ANA),	   anti-­‐lactoferrin	   (aLA)	   and	   anti-­‐carbonic	  anhydrase	  II	  (ACA	  II)	  (mostly	  unspecific	  to	  the	  disease	  but	  still	  more	  prevalent	   in	  AIP	  patients	  vs.	  non	  AIP	  patients).	  Finally,	  6)	  the	  common	  association	  with	  other	  autoimmune	  diseases	  and	  7)	  a	  positive	  response	  to	  steroid	  therapy	  strengthen	  this	  hypothesis.	  	  Findings	   regarding	   the	   etiology	   of	   AIP	   are	   various	   and	   heterogeneous,	   and	   point	   as	   well	   to	  possible	   alterations	   in	   cellular	   and	   humoral	   immune	   responses.	   Regarding	   cellular	   immune	  response	   in	  AIP,	  Okazaki	   et	   al.	   suggested	   that	   an	  elevation	  of	   the	  T	  helper	  1	   (Th1)	  over	   the	  T	  helper	  2	  (Th2)	  type	  immune	  response	  may	  be	  required	  for	  AIP	  pathogenesis(5).	  Conversely,	  Zen	  et	  al.	  showed	  a	  significant	  involvement	  of	  Th2	  in	  AIP	  pathogenesis(6).	  This	  later	  study	  involved	  AIP	  patients	  with	  positive	   IgG4	   immunostaining	  of	  extrapancreatic	  organs	   indicating	   that	   they	  included	  principally	  patients	  with	  type	  1	  AIP.	  These	  studies	  were	  performed	  at	  a	  time	  when	  the	  subtypes	   of	   AIP	   had	   not	   been	   individualized	   yet.	   Thereby,	   we	   can	   speculate	   that	   different	  findings	  could	  result	   from	  the	  fact	  that	  the	  pathogenesis	  of	  AIP	  subtypes	  may	  be	  distinct.	  With	  better	  recognition	  of	  these	  two	  subtypes,	  additional	  studies	  are	  required	  to	  demonstrate	  if	  both	  types	  of	  AIP	  with	   their	  differences	   in	  clinical	  profiles,	   age	  of	  appearance,	   sex	   ratio,	  geographic	  distribution,	  involvement	  of	  other	  organs	  and	  immunological	  signature	  have	  distinct	  pathogenic	  mechanism	  and	  by	  there	  distinct	  etiology.	  For	  this	  reason,	  as	  far	  as	  it	  is	  possible,	  it	  is	  important	  to	  always	  individualize	  both	  AIP	  subtypes	  whenever	  a	  question	  is	  assessed	  in	  the	  field	  of	  AIP.	  	  However,	  to	  explain	  the	  heterogeneous	  findings,	  several	  groups,	  including	  Park	  et	  al.	  suggested	  a	  biphasic	  model	  to	  explain	  AIP	  etiology,	  with	  first	  an	  initiation	  then	  a	  progression	  of	  the	  disease	  with	  the	  support	  of	  T	  regs	  (7)	  .	  This	  model	  is	  based	  on	  two	  main	  observations.	  	  1)	   Immunization	   with	   carbonic	   anhydrase	   II	   or	   lactoferrin	   of	   the	   thymectomized	   AIP	   mouse	  model	   induces	  an	   infiltration	  of	  CD4+	  T	  cells	  over	  B	  cells	   in	  different	  organs	  such	  as	  pancreas,	  salivary	  glands,	  and	  bile	  ducts	  that	  mimics	  type	  1	  AIP(8).	  	  The	  mouse	  model	  develops	  a	  depletion	  of	  naïve	  T	  regs	  in	  the	  periphery	  and	  MHC	  class	  II	  restricted	  autoreactive	  CD4+	  T	  cells,	  indicating	  that	   these	   two	   are	   crucial	   in	   the	   induction	   of	   systemic	   organ	   lesions.	   These	   CD4+T	   cells	  may	  activate	  macrophages	  and	  proinflammatory	  reactions	  during	  the	  early	  stage	  of	  AIP	  with	  a	  direct	  cytotoxic	   effect	   through	   Fas	   ligand	   expression(9).	   Furthermore,	   the	  WBN/Kob	   rat,	   that	   has	   a	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congenital	   decreased	   in	   peripheral	   T	   regs	   levels,	   develops	   spontaneously	   sialadenitis,	  thyroiditis,	   sclerosis	   cholangitis	   and	   tubulointerstitial	   nephritis.	   This	   observation	   strengthens	  the	  hypothesis	  that	  T	  regs	  depletion	  and	  CD4+	  T	  cells	  are	  important	  in	  the	  phase	  of	  initiation	  of	  AIP.	  2)	  Zen	  et	  al.	  showed	  a	  predominance	  of	  Th2	  over	  Th1	  immune	  response	  in	  AIP	  with	  the	  presence	  of	  a	   large	  number	  of	  T	  regs.	  They	  hypothesized	  that	  this	   large	  amount	  of	  Tregs	   is	   induced	  in	  a	  second	   step	   to	   inhibit	   an	   initial	   Th2	   immune	   reaction.	   Indeed,	   it	   is	   known	   that	   T	   regs	   are	  activated	  by	  excessive	  immune	  reactions	  in	  certain	  types	  of	  infections	  or	  allergic	  disorders	  and	  are	  known	  to	  prevent	  a	  Th2	  type	  immune	  response(10,11).	  	  	  Hence,	   the	   “biphasic	  model”	  would	   speculate	   that	   first,	   an	   immune-­‐inflammatory	   response	   to	  self-­‐autoantigens	   (aLF,	   ACA	   II,…)	   or	   to	   molecular	   mimicry	   (H.Pylori)	   induces	   the	   disease	   by	  activating	   antigen-­‐presenting	   cells	   and	   macrophages	   stimulation.	   Then,	   in	   the	   presence	   of	  decreased	   naïve	   T	   regs,	   Th1	   cells	   activate,	   release	   their	   cytokines	   and	   induce	   the	   cellular	  immune	  reaction.	  After	  and	  in	  response	  to	  Th1	  cells	  activation,	  T	  regs	  are	  stimulated	  and	  induce	  Th2-­‐cytokines	   release	   and	   activate	   the	   humoral	   response	   with	   production	   of	   IgG	   and	   IgG4	  autoantibodies.	   This	   concept	   suggests	   that	   the	   pathophysiology	   of	   AIP	   might	   resemble	   the	  Sjögren’s	   syndrome	   in	   which	   Th1	   cytokines	   may	   be	   needed	   for	   the	   initiation	   and/or	  maintenance	  of	  the	  disease,	  and	  Th2	  cytokines	  are	  important	  for	  disease	  progression.	  	  The	   lack	  of	   identification	  of	  patients	  with	  type	  1	  and	  type	  2	  AIP	   in	  these	  previous	  series	  make	  interpretation	  of	  these	  studies	  very	  difficult.	  This	  mixture	  of	  patients	  might	  be	  one	  of	  the	  reasons	  why	  findings	  about	  AIP	  are	  heterogeneous.	  	  	  The	  question	  we	  address	  in	  these	  experiments	  is	  to	  define	  the	  cytokine	  expression	  in	  sera	  and	  pancreatic	  tissues	  of	  type	  1	  and	  type	  2	  AIP,	   in	  order	  to	  see	  if	  there	  is	  a	  difference	  in	  these	  two	  groups.	  To	  be	  able	  to	  have	  a	  comparison	  in	  the	  amount	  of	  expression	  of	  these	  cytokines	  and	  to	  have	  relevance	  in	  clinical	  diagnosis,	  we	  decided	  to	  compare	  AIP	  groups	  with	  pancreatic	  cancer	  (PDAC)	  and	  chronic	  pancreatitis	  (CP),	  both	  difficult	  differential	  diagnosis	  of	  AIP.	  	  	  	  
Patients	  and	  samples:	  Patients	  were	  recruited	  from	  Heidelberg	  Hospital	  Clinic	  (Germany)	  and	  chosen	  according	  to	  the	  patient’s	  list	  we	  had	  in	  the	  European	  pancreatic	  center	  (EPC).	  There	  were	  selected	  depending	  on	  the	  availability	  and	  amount	  of	   samples	   (sera	  or	  pancreatic	   tissues)	  at	   the	   time	  of	  experiments	  and	   as	   the	   first	   in	   the	   list	  we	  had.	   	   Particular	   attention	  was	  paid	   in	   order	   to	  have	   as	  much	   as	  possible	   similar	   patients	   between	   the	   three	  different	   experiments.	   All	   pancreatic	   tissues	  were	  reviewed	  by	  a	  pathologist	  to	  confirm	  disease	  diagnosis	  (type	  1	  and	  type	  2	  AIP,	  PDAC	  and	  CP).	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1.	  Bio-­‐Plex®	  system	  in	  sera:	  The	  experiment	  included	  24	  different	  AIP	  patients	  from	  Heidelberg	  Hospital.	  Among	  patients,	  18	  had	  surgery	  between	  2004	  and	  2009	  and	  6	  patients	  had	  no	  operations.	  21	  were	  men	  and	  3	  were	  women	  with	  an	  average	  of	  51.79	  (SE=3.23)	  years	  old	  at	  the	  time	  of	  the	  operation	  for	  those	  who	  underwent	  surgery	  and	  at	   the	   time	  of	  diagnosis	   for	   those	  who	  had	  no	  surgery.	  The	  diagnostic	  was	   confirmed	   on	   the	   histology	   for	   patients	  who	   had	   surgery.	   For	   those	   you	   had	   no	   surgery,	  diagnosis	  was	  made	  according	   to	   the	  HISORts	  Mayo	   clinic	   criteria	   and	  effectiveness	  of	   steroid	  treatment.	  Eleven	  patients	  were	  type	  1	  AIP,	  6	  were	  type	  2	  AIP	  and	  7	  had	  no	  subtype	  defined.	  We	  had	  respectively	  21	  and	  22	  patients	  suffering	  of	  PDAC	  and	  CP.	  	  	  	   Total	   AIP	   	   CP	   PDAC	  	   	   AIP	  I	   AIP	  II	   AIP	  unknown	   	   	  Number	   of	  patients	   67	   24	   11	   6	   7	   22	   21	  Number	   of	  observa-­‐tions	   76	   33	   16	   9	   8	   22	   21	  Male	  #(%)	   50	  (74.6%)	   21	  (87.5%)	   11	  (100%)	   5	  	  (83.3%)	   5	  (71.4%)	   16	  (72.7%)	   13	  (61.9%)	  Mean	   age	   at	  operation	   time	  (standard	  error)1	  
57.49	  (1.97)	   51.79	  (3.23)	   55.18	  (3.21)	   34.67	  (2.79)	   61.14	  (6.70)	   53.00	  (3.26)	   68.71	  (2.53)	  
Table	  2:	  Sample	  used	  in	  the	  first	  experiment	  	  
2.	  Bio-­‐Plex®	  system	  in	  pancreatic	  tissues:	  In	   this	   experiment,	   pancreatic	   tissues	   from	   14	   AIP	   patients	   (4	   type	   1,	   5	   type	   2	   and	   5	  undetermined	   type),	   12	   CP	   and	   12	   PDAC	   were	   evaluated.	   In	   order	   to	   increase	   precision	   of	  results	   each	   sample	   was	   assessed	   twice	   and	   observations	   are	   mean	   values	   of	   two	   observed	  values.	   Gender	   distribution	   and	   mean	   age	   at	   the	   time	   of	   operation	   among	   the	   patients	   are	  reported	  in	  table	  3.	  	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  For	  6	  observations	  the	  age	  corresponds	  to	  the	  time	  of	  the	  diagnostic	  as	  no	  operation	  was	  done.	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   Total	   AIP	   	  	   CP	   PDAC	  	  	   	  	   AIP	  I	   AIP	  II	   AIP	  unknown	   	  	   	  	  
Number	   of	  patients	   38	   14	   4	   5	   5	   12	   12	  
Male	  #(%)	   30	  (78.9%)	   13	  (92.9%)	   4	  (100%)	   4	  (80.0%)	   5	  (100%)	   8	  (66.7%)	   9	  (75.0%)	  
Mean	   age	   at	  operation	   time	  (standard	  error)	   55.78	  (2.68)	   52.71	  (4.45)	   59.75	  (5.02)	   42.00	  (7.07)	   57.80	  (8.38)	   48.75	  (4.56)	   66.42	  (3.52)	  
Table	  3:	  Sample	  used	  in	  the	  second	  experiment	  
3.	  Immunohistochemistry(IHC)	  in	  pancreatic	  tissues:	  	  The	  study	  included	  29	  patients	  who	  had	  undergone	  surgery	  during	  the	  years	  of	  2004	  to	  2008.	  There	  are	  8	  AIP	  patients	  (5	  type	  1	  and	  3	  type	  2),	  10	  patients	  with	  CP	  and	  11	  patients	  with	  PDAC.	  22	  were	  men	  and	  7	  women	  with	  an	  average	  age	  of	  60.86	  (SE	  2.45,	  minimum	  age	  of	  39	  years	  old	  to	  a	  maximum	  age	  of	  80	  years	  old)	  at	  the	  time	  of	  surgery.	  Gender	  distribution	  and	  mean	  age	  at	  operation	  time	  for	  each	  groups	  are	  reported	  in	  table	  4.	  	   	   Total	   AIP	   	   	   CP	   PDAC	  	   	   	   AIP	  I	   AIP	  II	   	   	  Number	  of	  patients	   29	   8	   5	   3	   10	   11	  Male	  #(%)	   22	  (75.9%)	   7	  (87.5%)	   5	  (100%)	   2	  (66.7%)	   7	  (70.0%)	   8	  (72.7%)	  Mean	  age	  at	  operation	  time	  (standard	  error)*	  
60.86	  (2.45)	   57.75	  (4.59)	   63.20	  (3.75)	   48.67	  (9.17)	   55.50	  (4.84)	   68.00	  (2.48)	  
Table	  4:	  Sample	  used	  in	  the	  third	  experiment	  
Methods:	  
Bio-­‐Plex®	  system:	  For	  the	  two	  first	  experiments,	  cytokine	  levels	  in	  our	  samples	  were	  determined	  using	  a	  Bio-­‐Plex	  human	  cytokine	  17	  plex	  panel	  kit	  (Bio-­‐Rad)	  that	  was	  analyzed	  on	  the	  Bio-­‐Plex	  workstation	  of	  the	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European	  Pancreatic	  Center(EPC).	  Bio-­‐Plex	  cytokine	  assay	  is	  a	  bead-­‐based	  assay	  that	  quantifies	  17	  human	  cytokines	   in	  diverse	  materials	  such	  as	  serum	  or	  plasma.	  Using	  a	  96	  well	  microplate	  format	  it	  quantitates	  at	  a	  same	  time	  in	  a	  same	  liquid	  and	  under	  constant	  and	  equal	  conditions	  17	  cytokines	  over	  a	  broad	  dynamic	  range.	  These	  cytokines	  are	  IL-­‐2,	  4,	  5,	  6,	  7,	  8,	  10,	  12	  (p70),	  13,	  17,	  1β,	   G-­‐CSF,	   GM-­‐CSF,	   IFN-­‐γ,	   MCP-­‐1,	   MIP-­‐1β	   and	   TNF-­‐α.	   	   The	   kit	   includes	   a	   cytokine	   assay	   that	  contains	   antibody-­‐conjugated	   beads,	   detection	   antibody	   and	   antigen	   standards,	   a	   cytokine	  reagent	  kit	  with	  assay	  buffer,	  wash	  buffer,	  detection	  antibody	  diluent,	  streptavidin-­‐PE,	  96-­‐well	  filter	   plate,	   sealing	   tape	   and	   instruction	   manual	   and	   a	   diluent	   kit	   for	   sample	   and	   standard	  dilution.	  	  The	   concept	   of	   Bio-­‐Plex	   relies	   on	   assays	   on	   beads.	   Reactions	   take	   place	   on	   these	   beads	  while	  they	  are	   in	  suspension.	  Using	  a	   two-­‐dye	  method,	   luminex	  produce	  100	  distinct	  bead	  sets.	  Bio-­‐Plex	  uses	  these	  uniquely	  color-­‐coded	  bead	  sets	  to	  identify	  multiple	  assays	  in	  a	  single	  well.	  While	  suspended	  in	  a	  sample,	  the	  bound	  bind	  targeted	  molecules.	  Fluorescently	  labeled	  reporter	  tags	  (streptavidin	  PE)	  bind	   to	   the	  sample	  molecules.	  Precision	   fluidics	  align	   the	  beads	   in	  single	   file	  and	   pass	   them	   through	   the	   lasers	   one	   at	   a	   time.	   A	   red	   classification	   and	   green	   reporter	   laser	  illuminate	   individual	   beads	   to	   identify	   each	   bead’s	   spectral	   address	   and	   associated	   reporter	  signal.	   Concentrations	   (pg/ml)	   are	   calculated	   by	   Bio-­‐Plex	  Manager	   software	   using	   a	   standard	  curve	  derived	  from	  a	  recombinant	  isotype	  standard	  and	  are	  then	  reported	  into	  an	  excel	  file.	  
1.	  Bio-­‐Plex®	  system	  in	  sera:	  Sera	   from	  patients	  were	  pull	  out	   from	  main	   freezers	  of	   the	  EPC,	  depending	  on	   the	   list	  we	  had	  and	  were	  diluted	  1	  to	  4	  in	  assay	  buffer.	  Using	  the	  Bio-­‐Plex	  human	  cytokine	  17	  plex	  panel	  kit,	  we	  disposed	  on	  the	  96	  microplate	  8	  standard	  in	  duplicate,	  2	  blank	  solutions,	  34	  AIP,	  22	  PDAC	  and	  22CP.	  	  We	   first	   prewet	   the	   filter	  plate	   and	   add	  beads.	  We	  washed	  2	   times	   and	   add	  50μl	   of	   standard,	  blank	  or	  sample	  depending	  on	  the	  wall	  and	  incubate	  30	  min.	  Then,	  we	  washed	  and	  filtered	  the	  plate	   3	   times,	   add	   25	   μl	   of	   detection	   antibody	   and	   incubate	   it	   during	   30	   minutes.	   Again,	   we	  washed	  and	  filtered	  the	  plate	  3	  times.	  50	  μl	  of	  streptavidin-­‐PE	  were	  added	  to	  stop	  the	  reaction	  and	  the	  plate	  was	  incubated	  10	  minutes.	  We	  washed	  and	  filtered	  it	  3	  more	  times	  and	  beads	  were	  resuspended	  with	  125μl	  of	  assaybuffer.	  After	  a	  strong	  shake	   the	  plate	  was	  read	  using	   the	  Bio-­‐Plex	  reader	  computer.	  	  	  
2.	  Bio-­‐Plex®	  system	  in	  pancreatic	  tissues:	  First	   all	   tissues	  were	   cut	   in	   slides	   of	   9	   μm	   and	  mixed	   in	   a	   cell	   lysis	   solution	   containing	   lysis	  buffer,	  factor	  1,	  factor	  2	  and	  a	  protease	  inhibitor	  (phenylmethylsulfonyl	  fluoride,	  PMSF)	  from	  the	  Bio-­‐Plex	  cell	  lysis	  kit	  product	  insert	  of	  Bio-­‐Rad.	  Each	  tube	  was	  then	  incubated	  during	  a	  period	  of	  minimum	  24	  hours	  in	  -­‐80°C.	  Using	  the	  SonoPuls	  mini	  20	  Bandelin®,	  an	  ultrasonic	  homogenizer,	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each	  solution	  was	  homogenate	  and	  then	  centrifuged	  at	  4°	  during	  15	  minutes.	  The	  supernatant	  was	  collected.	  	  The	  protein	  concentrations	  in	  the	  supernatant	  were	  quantified	  using	  the	  ELISA	  system	  in	  order	  to	  be	  adjusted	  to	  600	  μg/ml	  in	  each	  sample	  of	  our	  assays.	  	  On	  the	  96	  microplate	  we	  disposed	  8	  standard,	  1	  blank	  solution,	  14	  AIP,	  13	  PDAC	  and	  12	  CP	  all	  else	  in	  duplicate.	  Then,	  the	  experiment	  was	  run	  as	  described	  above	  with	  the	  sera.	  	  	  
3.	  IHC	  in	  pancreatic	  tissues:	  Distribution	   and	   intensity	   of	   9	   cytokines	   were	   evaluated	   on	   immunohistological	   stained	  pancreatic	   tissues.	   These	   cytokines	  were	   endocan,	   TNF-­‐α,	   IFN-­‐γ,	   IL-­‐6,	   IL-­‐8,	   IL-­‐10,	   IL-­‐12,	   IL-­‐17	  and	  IL-­‐23.	  For	  this,	  pancreatic	  tissues	  fixed	  in	  formalin	  and	  embedded	  in	  paraffin	  (using	  ASP	  300	  Leica®)	  were	  collected	  from	  the	  storage	  of	  the	  European	  Pancreatic	  Center	  and	  cut	  into	  4µm	  thick.	  They	  were	  deparaffinized	   into	  decreasing	  concentration	  of	  ethanol.	  To	  break	   the	  methylene	  bridges	  and	  expose	  the	  antigenic	  sites	  to	  allow	  the	  antibodies	  to	  bind,	  we	  used	  a	  heat-­‐induced	  epitope	  retrieval	  method	  with	  citrate	  buffer	  that	  we	  heated	  in	  the	  microwave	  (at	  60°C).	  Dilutions	  of	  the	  primary	   and	   secondary	   antibodies	   were	   determined	   by	   testing	   a	   range	   according	   to	   the	  recommended	   concentration	   in	   the	   datasheets	   and	   are	   listed	   in	   table	   5.	   To	   estimate	   the	  contribution	  of	   the	  non-­‐specific	   interaction	  and	  Fc	  receptor	  binding,	  control	  has	  been	  made	   in	  parallel	  for	  each	  slide	  (reagent	  used	  are	  listed	  in	  the	  table	  5).	  Time	  of	  coloration	  was	  determined	  under	  the	  microscope	  for	  each	  cytokines	  at	  the	  chosen	  concentration.	  All	  tissues	  were	  stained	  by	  hand	  as	  soon	  as	  all	  antibodies	  parameters	  were	  known	  and	  tested.	  Some	  tissues	  were	  detached	  from	  the	  slide	  or	  were	  not	  stained	  well;	  for	  this	  reason	  they	  were	  not	  taken	  into	  consideration	  for	  the	  statistical	  analyze.	  	  	  Hematoxylin	  and	  eosin	  (H&E)	  staining	  was	  performed	  for	  each	  tissue	  to	  confirm	  the	  diagnosis.	  Furthermore,	   each	   slide	  was	   stained	  with	   an	   anti-­‐CD3	   antibody.	   These	   slides	  were	   used	   as	   a	  reference	   to	   the	   distribution	   and	   localization	   of	   T	   cells	   in	   each	   tissue.	   	   Then,	  immunohistochemistry	   for	  each	  cytokine	  was	  performed	  using	   the	  peroxidase-­‐anti-­‐peroxidase	  (PAP)	  method	  well	  known	  in	  the	  laboratory.	  	  	  All	  slides	  were	  conserved	   in	  the	  European	  Pancreatic	  Center	  of	  Heidelberg.	  Dr	  Gaida	   from	  the	  Pathology	  department	  of	  Heidelberg	  Hospital,	  a	  specialist	  in	  pancreatic	  tissues	  lecture,	  read	  the	  slides	  and	  evaluated	   the	  distribution	  and	   the	   intensity	  of	  each	  cytokines	  grading	  each	  of	   them	  from	   0	   to	   3	   subjectively.	   Mean	   grade	   of	   intensity	   and	   distribution	   for	   each	   cytokines	   in	   each	  disease	  are	  reported	  in	  tables	  7	  and	  8	  respectively.	  	  	   	  
	   	  
	   	   	   9	  
	   	  
	   	   	  10	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Statistic	  methods:	  
1.	  Bio-­‐Plex®	  system	  in	  sera:	  Results	   on	   the	   Bio-­‐Plex	  Manager	   software	  were	   converted	   into	   an	   excel	   file.	   Two	  walls	   (X40,	  X19)	   could	   not	   be	   interpreted	   because	   of	   an	   error	   of	   manipulation	   (as	   agglutination)	   and	  aberrant	  concentration	  respectively.	  For	  this	  reason	  they	  have	  been	  deleted.	  For	  some	  patients	  several	   measurements	   are	   made	   over	   time	   and	   to	   increase	   the	   precision	   of	   results	   all	  measurements	   are	   kept	   and	   used	   in	   following	   analyses;	   thus	   some	   patients	   contribute	   to	   our	  analyses	  several	  times.	  Number	  of	  patients	  and	  observations	  are	  reported	  in	  table	  2.	  	  Cytokines	  are	  measured	  over	  an	  operational	  detection	  range	  and	  their	  mean	  concentrations	  are	  reported	   in	   table	   12.	   Measurements	   are	  made	   using	   Bio-­‐Plex	   kit	   as	   described	   above	   over	   an	  operational	   detection	   range.	   In	   other	   words	   if	   some	   observations	   are	   higher	   or	   lower	   than	  operational	  detection	  limits	  then	  the	  measured	  values	  are	  not	  reliable	  and	  should	  be	  considered	  as	  censored	  values.	  
Fitting	  a	  model	  to	  censored	  interdependent	  response	  variable	  The	   complicated	   nature	   of	   response	   variable	   under	   study	   imposes	   some	   sort	   of	   difficulty	   for	  analyzing	   them.	   To	   fit	   an	   ordinary	   linear	   model	   to	   a	   response	   variable	   we	   need	   to	   have	  independent	   observations;	   the	   lack	   of	   independence	   is	   apparent	   in	   our	   current	   sample	   as	  we	  have	  several	  measurements	  made	  on	   the	  same	   individual.	  The	  other	  difficulty	  arises	  when	  we	  notice	   the	   fact	   that	   some	   observations	   are	   actually	   lower	   than	   the	   detection	   limit	   of	  measurement	   tool.	   Thus,	   the	   response	   variable	   is	   censored	   below	   a	   certain	   limit	   and	   can’t	   be	  measured	  correctly.	  	  We	  chose	  to	  use	  the	  so	  called	  “tlmec”	  function	  of	  Ri2	  which	  can	  be	  used	  to	  fit	  linear	  mixed	  effect	  models	  on	  response	  variables	  which	  are	  censored	  below	  a	  certain	  level.	  The	  mixed	  effect	  linear	  model	  is	  a	  more	  general	  case	  of	  linear	  models	  where	  a	  random	  effect	  is	  also	  added	  to	  the	  model,	  mixed	   linear	   models	   are	   widely	   used	   when	   some	   interdependence	   is	   present	   in	   the	   sample	  structure.	   The	   inclusion	   of	   random	   effects	   in	   the	   patient	   level	   is	   necessary	   in	   our	   analyses	   as	  several	  patients	   contribute	   to	   fit	  models	  with	  more	   than	  one	  observation	  and	   so	  observations	  cannot	  be	  considered	  as	  independent.	  By	  fitting	  a	  linear	  mixed	  model	  (with	  capability	  of	  handling	  censored	  response	  in	  our	  case)	  to	  a	  response	   variable	   versus	   a	   categorical	   factor,	   with	   P	   factors	   for	   example,	   the	   model	   has	   to	  choose	   a	   reference	   category	   and	   compare	   other	   categories	   of	   the	   factor	   versus	   the	   reference	  category	   by	   estimating	   P-­‐1	   parameters.	   The	   comparison	   among	   other	   categories	   however	  cannot	  be	  performed;	  to	  do	  so	  a	  separate	  set	  of	  comparisons	  should	  be	  performed.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  Larissa	  Matos,	  Marcos	  Prates	  and	  Victor	  Lachos	  (2012).	  tlmec:	  Linear	  Student-­‐t	  Mixed-­‐Effects	  Models	  with	  Censored	  Data.	  R	  package	  version	  0.0-­‐2.	  http://CRAN.R-­‐project.org/package=tlmec	  
	   	  
	   	   	  12	  
After	   fitting	   the	   “tlmec”	  model	   several	   times	   (to	   be	   able	   to	  make	   necessary	   comparisons)	  we	  adjusted	  our	  results	  using	  the	  Bon-­‐Ferroni	  correction	  for	  multiple	  comparisons	  in	  order	  to	  avoid	  inflation	   in	   the	   first	   error	   rate	   whenever	   the	   model	   is	   refitted.	   All	   comparisons	   on	   different	  cytokines	   were	   done	   twice,	   once	   comparisons	   were	   done	   comparing	   AIP	   versus	   PDAC	   and	  CP	  patients	  and	  then	  all	  models	  were	  re-­‐fitted	  to	  compare	  among	  type	  1	  and	  type	  2	  AIP,	  PDAC	  and	  CP	  groups.	  In	  the	  first	  series	  the	  reference	  category	  is	  always	  AIP	  while	  in	  the	  second	  series	  AIP	  group	  is	  subdivided	  into	  two	  categories	  type	  1	  and	  2	  AIP,	  each	  one	  of	  these	  sub-­‐categories	  is	  once	  considered	  as	  the	  reference	  category	  and	  all	  desired	  analyses	  were	  performed	  twice	  (once	  with	  type	  1	  AIP	  and	  once	  with	  type	  2	  AIP	  as	  the	  reference	  category);	   the	  results	  of	   the	  second	  series	  are	  thus	  adjusted	  for	  multiple	  comparisons	  using	  Bon-­‐Ferroni	  correction.	  
	  
2.	  Bio-­‐Plex®	  system	  in	  pancreatic	  tissues:	  The	   concentration	   of	   each	   cytokine	   in	   this	   experiment	   is	   measured	   twice	   for	   each	   individual	  sample	   and	   the	  mean	   observation	   is	   used	   as	   the	   only	   observation	  made	   on	   that	   sample;	   this	  leads	   to	   a	   more	   precise	   estimate	   of	   the	   cytokine	   concentration	   with	   less	   variation;	   from	   the	  statistical	   point	   of	   view	   this	   loss	   of	   variation	  might	   be	   equivalent	   to	   a	   loss	   of	   information	  but	  instead	  we	  will	  be	  able	  to	  use	  a	   less	  complicated	  statistical	  analysis	  method	  as	  each	   individual	  contributes	  once	  to	  the	  analysis	  at	  hand.	  To	  avoid	  the	  out	  of	  practical	  range	  observations	  different	  dilutions	  have	  been	  tested,	  however,	  some	   observations	   are	   still	   lower	   than	   the	   practical	   observation	   range	   of	   machines	   we	   have	  used.	  These	  out	  of	  range	  values	  should	  not	  be	  considered	  as	  missing	  values	  and	  are	  contributing	  to	  our	  analysis	  as	  censored	  data.	  On	  the	  other	  hand,	  because	  of	  an	  important	  number	  of	  out	  of	  range	  values	  in	  IL-­‐5	  concentrations,	  they	  could	  not	  be	  interpreted	  and	  they	  were	  hence	  deleted.	  	  
Censored	  Regression	  model	  The	   linear	   regression	   is	  perhaps	   the	  basis	  of	  modern	   statistics	   and	  plays	  an	   important	   role	   in	  statistical	   modeling	   of	   data.	  We	   however	   cannot	   use	   the	   ordinary	   linear	   regression	  model	   in	  comparing	   cytokine	   concentrations	   among	   different	   groups	   of	   our	   sample.	   The	   censored	  regression	  (12)	  is	  a	  generalization	  of	  ordinary	  linear	  regression	  in	  which	  some	  observations	  can	  be	  censored	  (from	  left	  or	  right).	  Individuals	   have	   contributed	   only	   once	   to	   each	   model	   and	   thus	   there	   is	   no	   need	   to	   add	   the	  individual	  random	  effects	  for	  each	  patient.	  	  Two	  series	  of	  models	  are	   fitted	   to	   compare	   the	   concentration	  of	   each	  cytokine	  among	  groups.	  The	  first	  series	  of	  models	  compare	  these	  concentrations	  among	  CP	  and	  PDAC	  versus	  AIP	  without	  distinguishing	  among	  type	  1	  and	  type	  2	  AIP	  patients.	  The	  AIP	  group	  is	  the	  reference	  category	  for	  making	   comparisons,	   consequently	   no	   multiple	   comparisons	   adjustment	   is	   necessary	   to	   be	  applied	  in	  this	  case	  as	  no	  comparison	  is	  made	  among	  CP	  and	  PDAC	  groups.	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In	   the	   second	  series	  of	   analyses	  we	  have	  compared	  all	   groups	  versus	   type	  1	  AIP	  and	   then	   the	  same	   comparison	   is	   done	   comparing	   all	   groups	   versus	   type	   2	   AIP.	   Results	   for	   these	   analyses	  were	   adjusted	   for	   multiple	   comparisons	   as	   two	   models	   were	   fitted	   for	   each	   series	   of	  comparisons.	  Again	  no	  comparison	  is	  made	  between	  CP	  and	  PDAC	  groups.	  	  
3.	  IHC	  in	  pancreatic	  tissues:	  We	   first	   analyzed	   each	   cytokine	   distribution	   and	   intensity	   using	   a	   Kruskall-­‐Wallis	   test	   to	  compare	  AIP	  patients	  and	  reciprocally	  type	  1	  and	  type	  2	  AIP	  patients	  to	  CP	  and	  PDAC	  patients.	  Kruskall-­‐Wallis	   is	   a	   non-­‐parametric	   equivalent	   to	   the	   one-­‐way	   ANOVA	   (Analysis	   of	   Variance)	  test	  which	  is	  used	  to	  assess	  the	  influence	  of	  a	  factor	  with	  more	  than	  two	  categories	  (group	  in	  our	  case)	   on	   a	   continuous	   variable,	   however	   the	   nonparametric	   nature	   of	   the	   Kruskal-­‐Wallis	   test	  makes	  it	  robust	  compared	  to	  the	  ANOVA.	  Furthermore,	  to	  study	  the	  observed	  intensity	  and	  distribution	  for	  each	  cytokine	  simultaneously	  one	  may	  suggest	  combining	  two	  variables	  into	  one	  overall	  variable.	  A	  simple	  choice	  would	  be	  to	  use	  the	  sum	  of	  two	  variables	  as	  a	  general	  summary	  but	  this	  strategy	  results	  in	  similar	  values	  for	  cases,	  which	  are	  considered	  to	  be	   far	  apart	   from	  each	  other.	  The	  other	  possibility	  would	  be	  to	  use	   the	   multiplication	   of	   intensity	   and	   distribution	   but	   this	   inflates	   the	   range	   of	   combined	  variable	   dramatically.	   Thus	   by	   mixing	   these	   ideas	   we	   decided	   to	   use	   the	   combined	   variable	  described	  below	  as	  the	  summary	  of	  both	  variables:	  	   𝑐𝑜𝑚𝑏𝑖𝑛𝑒𝑑  𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒 = 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 + 𝑑𝑖𝑠𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛 + 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦×𝑑𝑖𝑠𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛2 ,	  	  which	  combines	  two	  variables	  more	  adequately.	  Then,	  we	  analyzed	  this	  combined	  information	  using	   same	   statistical	   test.	  Whenever,	  more	   than	   one	   test	   is	   run	   to	   described	   the	   comparison	  between	   a	   group	   we	   corrected	   the	   p	   value	   using	   the	   Bonferroni-­‐correction	   for	   multiple	  comparison	  test.	  	  
Results:	  P-­‐value	  lower	  than	  0.05	  are	  considered	  to	  be	  statistically	  meaningful	  (or	  significant).	  Results	  for	  each	   experiment	   are	   listed	   in	   table	   9,	   10	   and	   11.	   The	   cytokine	   name	   and	   the	   performed	  comparison	  are	  listed	  in	  the	  first	  two	  columns.	  The	  third	  column	  corresponds	  to	  the	  estimated	  coefficient	  of	   the	  model,	  which	   can	  be	   interpreted	  as	   the	   controlled	  average	  difference	  among	  compared	   categories.	   The	   fourth	   columns	   report	   original	   or	   corrected	   p-­‐values	   whenever	   a	  multiple	  comparison	  correction	  has	  been	  necessary.	  
	   	  
	   	   	  14	  
Regarding	  the	  results,	  relevant	  findings	  are	  represented	  using	  graphical	  tools.	  We	  have	  chosen	  to	   use	   the	   box-­‐plots	   of	   observations	   inside	   the	   operational	   measurement	   range	   to	   show	   the	  centrality	   and	  variation	  of	  observed	  values	   simultaneously.	  These	  graphics	   are	   represented	   in	  figure	  1	  and	  2.	  Results	   should	   be	   interpreted	  with	   caution	  whenever	   too	  many	   observations	   are	   outside	   the	  operational	  measurement	  range	  and	  hence	  the	  number	  of	  observation	  (n)	  is	  too	  low.	  	  Mean	  cytokine	  concentrations	  in	  the	  sera	  and	  pancreatic	  tissues	  are	  reported	  in	  table	  12	  and	  13	  (Annexes).	  
	  
1.	  Bio-­‐Plex®	  system	  in	  sera:	  IL-­‐8	  and	  MIP-­‐1b	  are	  highly	  expressed	  in	  the	  sera	  of	  patients	  suffering	  of	  type	  2	  AIP	  than	  type	  1	  AIP.	  On	  the	  other	  hand,	  cytokine	  as	  IL-­‐6,	  G-­‐CSF,	  MCP-­‐1	  are	  significantly	  more	  expressed	  in	  PDAC.	  	  Cytokine	   Description	   Coefficient	   P-­‐value	  
IL-­‐6	  
PDAC	  vs	  AIP	   59.73	   0.0001	  PDAC	  vs	  AIP1	   64.79	   0.0017	  PDAC	  vs	  AIP2	   59.41	   0.0126	  
IL-­‐8	  
AIP2	  vs	  AIP1	   44.04	   0.0535	  AIP1	  vs	  AIP2	   -­‐44.04	   0.0535	  
G-­‐CSF	  
PDAC	  vs	  AIP	   23.69	   0.0001	  PDAC	  vs	  AIP1	   24.41	   0.0018	  PDAC	  vs	  AIP2	   21.44	   0.0210	  
MCP-­‐1.MCAF	  
PDAC	  vs	  AIP	   42.15	   0.0006	  PDAC	  vs	  AIP1	   48.41	   0.0023	  PDAC	  vs	  AIP2	   37.65	   0.0476	  
MIP.1b	  
AIP2	  vs	  AIP1	   100.16	   0.0179	  AIP1	  vs	  AIP2	   -­‐100.16	   0.0179	  PDAC	  vs	  AIP2	   -­‐94.84	   0.0191	  CP	  vs	  AIP2	   -­‐90.42	   0.0244	  
Table	  5:	  Relevant	  findings	  in	  the	  first	  experiment	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Figure	  2:	  Comparison	  of	  the	  concentrations	  of	  different	  cytokines	  in	  the	  sera,	  n	  =	  number	  of	  observations	  per	  
group	  in	  the	  operational	  measurement	  range	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2.	  Bio-­‐Plex®	  system	  in	  pancreatic	  tissues:	  IL-­‐8	  and	  MCP-­‐1	  are	  highly	  expressed	  in	  the	  pancreatic	  tissues	  of	  type	  2	  compared	  to	  type	  1	  AIP.	  IL-­‐1b	  is	  more	  expressed	  in	  AIP	  than	  CP	  and	  PDAC	  while	  IL-­‐13	  is	  less	  expressed	  in	  AIP	  compared	  to	  CP	  and	  PDAC.	  	  Interestingly,	  concentration	  of	  IL-­‐17	  is	  higher	  in	  type	  2	  AIP	  than	  CP	  while	  IL-­‐10	  is	  more	  expressed	  in	  CP	  than	  type	  1	  AIP.	  	  
	  
Table	  6:	  Relevant	  results	  in	  the	  second	  experiment	  
Cytokine	   Description	   Coefficient	   P-­‐value	  
IL-­‐1	  b	  
CP	  vs	  AIP	   -­‐2.66	   0.0206	  
PDAC	  vs	  AIP	   -­‐1.85	   0.1074	  
CP	  vs	  AIP1	   -­‐3.59	   0.0701	  	  
IL-­‐8	  
AIP1	  vs	  AIP2	   -­‐320.78	   0.0294	  
CP	  vs	  AIP2	   -­‐268.28	   0.0203	  	  
IL-­‐10	  
CP	  vs	  AIP	   0.34	   0.0795	  
CP	  vs	  AIP1	   0.60	   0.0190	  	  
IL-­‐13	  
CP	  vs	  AIP	   4.18	   0.0048	  
PDAC	  vs	  AIP	   3.10	   0.0368	  
CP	  vs	  AIP1	   5.33	   0.0243	  
PDAC	  vs	  AIP1	   4.24	   0.0900	  
CP	  vs	  AIP2	   4.62	   0.0398	  	  
IL-­‐17	  
CP	  vs	  AIP	   -­‐12.25	   0.0161	  
CP	  vs	  AIP2	   -­‐16.30	   0.0437	  	  
MCP-­‐1	  
CP	  vs	  AIP	   -­‐222.96	   0.0291	  
AIP2	  vs	  AIP1	   389.65	   0.0368	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Figure	  3	  :	   Comparison	  of	   the	   concentrations	  of	  different	   cytokines	   in	   the	  pancreatic	   tissues,	  n	  =	  number	  of	  
observations	  per	  group	  in	  the	  operational	  measurement	  range	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3.	  IHC	  in	  pancreatic	  tissues:	  	   Description	   P-­‐value	  
Endocan	  distribution	   AIP	  vs	  PDAC	   0.0030	  AIP1	  vs	  PDAC	   0.0232	  AIP2	  vs	  PDAC	   0.0967	  	  Endocan	  
combined	  distribution	  and	  intensity	  
AIP	  vs	  PDAC	   0.0409	  
	  TNFa	  distribution	   AIP	  vs	  CP	   0.0126	  AIP1	  vs	  CP	   0.0534	  	  TNFa	  intensity	   AIP	  vs	  PDAC	   0.0603	  	  TNFa	  combined	  distribution	  and	  intensity	   AIP	  vs	  PDAC	   0.0932	  AIP	  vs	  CP	   0.0106	  AIP1	  vs	  CP	   0.0596	  	  IL-­‐6	  distribution	   AIP	  vs	  CP	   0.0473	  	  IL-­‐6	  intensity	   AIP	  vs	  PDAC	   0.0685	  	  IL-­‐6	  combined	  distribution	  and	  intensity	   AIP	  vs	  PDAC	   0.0843	  	  IL-­‐10	  distribution	   AIP	  vs	  PDAC	   0.0007	  AIP1	  vs	  PDAC	   0.0098	  AIP2	  vs	  PDAC	   0.0089	  	  IL-­‐10	  combined	  distribution	  and	  intensity	   AIP	  vs	  PDAC	   0.1025	  AIP2	  vs	  PDAC	   0.0467	  
	  
Table	  7:	  List	  of	   cytokine-­‐related	  variables	  where	  a	   significant	   (or	   important)	  difference	   is	  observed	  among	  
groups	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Mainly,	   endocan	   and	   IL-­‐10	  were	  more	   distributed	   in	   the	   pancreatic	   tissues	   of	   PDAC	   patients	   than	   AIP	  patients	  (Fig.3),	  while	  distribution	  of	  IL-­‐6	  and	  TNF-­‐α,	  pro-­‐inflammatory	  cytokines	  were	  more	  important	  in	  CP	  than	  AIP	  (Fig.4).	  
	  
Figure	   4	  :	   P-­‐IHC	   staining	   of	   	   endocan	   and	   IL-­‐10	   in	   AIP	   (left	   side)	   and	   PDAC	   (right	   side)	   patients	   (low	  
magnitude)	  
	  
Figure	  5:	  P-­‐IHC	  staining	  of	  TNF	  alpha	  and	  IL-­‐6	  in	  AIP	  (left	  side)	  and	  CP	  (right	  side)	  patients	  (low	  magnitude)	  
Discussion:	  Cytokine	  expressions	  in	  the	  sera	  and	  pancreatic	  tissues	  of	  both	  types	  of	  AIP	  have	  been	  evaluated.	  It	  results	  that	  three	  cytokines	  are	  significantly	  increased	  in	  type	  2	  AIP	  compared	  to	  type	  1	  AIP.	  These	  cytokines	  are	  interleukin-­‐8	   (IL-­‐8),	   macrophage	   inflammatory	   protein-­‐1	   beta	   (MIP-­‐1b)	   and	   monocyte	   chemotactic	  protein-­‐1	  (MCP-­‐1).	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In	  our	  experiment,	  MIP	  1	  beta	  is	  more	  expressed	  in	  the	  sera	  of	  patients	  suffering	  of	  type	  2	  AIP	  compared	  to	   type	   1	   AIP,	   PDAC	   or	   CP.	   Macrophage	   Inflammatory	   Protein	   is	   a	   chemotactic	   cytokine	   that	   induce	  directed	   chemotaxis	   in	   nearby	   stimulated	   cells;	   in	   other	   word	   it	   is	   a	   CC-­‐chemokine.	   Its	   function	   is	   to	  activate	   human	   granulocytes	   (neutrophils,	   eosinophils	   and	   basophils),	   which	   can	   lead	   to	   acute	  neutrophilic	   inflammation.	   MIP-­‐1a	   together	   with	   MIP-­‐1b	   induce	   synthesis	   and	   release	   of	   other	   pro-­‐inflammatory	  cytokines	  such	  as	   interleukin-­‐1	   (IL-­‐1),	   IL-­‐6	  and	  TNF-­‐α	   from	   fibroblasts	  and	  macrophages.	  These	  chemokines	  induce	  chemotaxis	  and	  adhesion	  of	  circulating	  leukocytes	  for	  their	  extravasation	  that	  occurs	  with	  destruction	  of	  the	  pancreatic	  epithelial	  ducts.	  However,	  since	  no	  correlation	  has	  been	  proved,	  it	   is	   likely	   that	   this	   chemokine	   is	   only	   one	   among	   several	   factors	   responsible	   for	   the	   recruitment	   of	  macrophages	  in	  acini	  lumen.	  However,	  this	  recruitment	  depends	  not	  only	  on	  the	  gradient	  of	  chemokines,	  but	   also	   on	   several	   successive	   steps,	   including	   adherence,	   rolling	   and	   extravasion,	   regulated	   by	  proinflammatory	   cytokines.	   Schrum	   et	   al.	   observed	   that	   MIP-­‐1b	   are	   secreted	   by	   T	   lymphocytes	  particularly	  Th1	  phenotype	  (13).	  Moreover,	  Bystry	  et	  al.	  (14)showed	  that	  activation	  of	  B	  cells	  and	  antigen	  presenting	  cells	  (APCs),	  induce	  the	  expression	  of	  MIP-­‐1b	  that	  recruit	  regulatory	  T	  cells	  (CD4+	  CD25+Tcell	  population)	   that	  are	  also	   reported	   to	  be	   increased	   in	  AIP.	   Indeed,	   they	   showed	   that,	  depletion	  of	  either	  regulatory	  Tcells	  or	  MIP-­‐1b	  result	  in	  the	  disregulation	  of	  humoral	  response	  that	  leads	  to	  the	  production	  of	  autoantibodies	  and	  then	  autoimmune	  activation.	  Bustry	  et	  al.	  showed	  that	  activated	  B	  cells	  express	  factors	  that	  strongly	  attracted	  regulatory	  T	  cells	  (that	  express	  both	  TGF-­‐β	  and	  CTLA-­‐4	  and	  unable	  to	  respond	  to	  anitCD3	  stimulation)	  and	  that	  MIP-­‐1b	  one	  of	  the	  chemokines	  that	  are	  strongly	  induced	  upon	  stimulation	  was	  sufficient	  to	  confer	  this	  effect.	  Furthermore,	  they	  found	  that	  CCR5	  that	  is	  though	  to	  be	  the	  receptor	  for	  MIP-­‐1b	   was	   expressed	   on	   these	   CD4+CD25+T	   cells.	   Given	   the	   role	   of	   regulatory	   T	   cells	   in	   suppressif	  cytotoxic	  T	  cell	  autoreactivity,	  the	  recruitement	  of	  regulatory	  T	  cells	  by	  APCs	  via	  these	  chemokines	  could	  be	  a	  general	  mechanism	  for	  regulating	  immune	  responses	  and	  contra-­‐regulating	  autoimmunity.	  	  Regarding	   the	   function	  of	  MIP	  1beta,	   these	  results	  support	  an	   involvement	  of	   the	  CC-­‐chemokines	   in	   the	  inflammatory	   reaction	   or	   maintenance	   of	   inflammation	   in	   type	   2	   AIP.	   We	   hypothesize	   that	   those	   T	  lymphocytes	  in	  type	  2	  AIP	  might	  be	  of	  the	  Th1	  subset	  and	  that	  neutrophilic	  epithelial	  lesions	  described	  as	  GELs	  in	  this	  subtype	  of	  AIP	  may	  be	  induced	  by	  MIP-­‐1b.	  	  Monocyte	  chemotactic	  protein-­‐1	  (MCP-­‐1)	  is	  another	  CC-­‐chemokine	  secreted	  by	  monocytes,	  macrophages	  and	  dendritic	  cells	  and	  its	   function	  is	  to	  recruit	  monocyte,	  memory	  T	  cells	  and	  natural	  killer	  cells	   to	  the	  site	  of	  inflammation	  in	  time	  of	  infection	  or	  tissue	  injuries(15).	  MCP-­‐1	  has	  long	  been	  described	  as	  having	  a	  chemotactic	  activity	  for	  monocytes	  and	  basophils	  but	  not	  for	  neutrophils	  and	  eosinophils.	  Furthermore,	  it	  is	   a	   strong	   recruiter	   of	   lymphocytes	   from	   the	   bloodstream	   into	   inflammatory	   lesions.	   Carr	   et	   al.	  (16)showed	   that	   this	   chemoattractant	   function	   is	   dose-­‐dependant	   and	   due	   to	   chemotaxis	   rather	   than	  chemokinesis.	   This	   chemokine	   was	   also	   reported	   to	   be	   implicated	   in	   several	   disease	   characterized	   by	  monocytic	  infiltrates,	  such	  as	  multiple	  sclerosis(17),	  psoriasis,	  rheumatoid	  arthritis(18),	  artherosclerosis	  (19)	   and	   insulin-­‐resistant	   diabetes(20).	   Not	   only	   MCP-­‐1	   act	   on	   recruiting	   and	   directing	   leukocytes	  movement	  but	   it	   also	   influence	  T-­‐cell	   immunity.	   Indeed,	   it	   is	   though	   that	  MCP-­‐1	  may	  play	   a	   role	   in	   the	  polarization	  of	  Th0	  cells	  toward	  a	  Th2	  phenotype	  via	  activation	  of	  the	  IL-­‐4	  promoter(21,22).	  In	  our	  study,	  MCP-­‐1	  was	  significantly	  more	  expressed	  in	  pancreatic	  tissues	  of	  type	  2	  AIP	  patients.	  On	  the	  other	  hand,	  its	  concentrations	  was	  not	  more	  elevated	  in	  the	  sera	  of	  type	  2	  AIP	  patient	  or	  other	  AIP	  groups	  (type	  1	  or	  total	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AIP	  patients)	  while	   it	  was	   increased	   in	  PDAC.	   It	   is	   interesting	   to	   see	   that	   because	  MCP-­‐1	   function	   is	   to	  recruit	  T	   cells,	   one	   could	   imagine	   that	   it	  would	  be	   increased	   in	  pancreatic	   tissues	  of	  both	  AIP	   subtypes	  since	   they	   are	   characterized	   by	   a	   lymphoplasmocytic	   infiltration	   in	   the	   pancreatic	   parenchyma.	   To	   our	  knowledge	  the	  lymphocytes	  infiltrates	  have	  not	  been	  described	  in	  a	  higher	  amount	  in	  type	  2	  AIP	  than	  type	  1.	  Hence,	  increased	  MCP-­‐1	  concentration	  in	  the	  pancreas	  of	  type	  2	  AIP	  can	  not	  be	  explained	  by	  a	  higher	  T	  cell	  infiltrations.	  Moreover,	  because	  MCP-­‐1	  is	  associated	  with	  a	  Th2	  polarization,	  it	  would	  mean	  that	  Th2	  cells	  over	  Th1	  is	  required	  in	  the	  pathogenesis	  of	  type	  2	  AIP.	  	  IL-­‐8,	   also	   known	   as	   neutrophil	   chemotactic	   factor,	   is	   a	   neutrophil-­‐activating	   cytokine	   released	   via	  chemotaxis	  and	  exocytosis	  of	  granule	  enzyme	  by	  phagocytes	  and	  different	   tissue	  cells	  such	  as	  epithelial	  cells	  or	  neutrophils	  itself	  when	  they	  are	  exposed	  to	  inflammatory	  environments(23).	  IL-­‐1	  and	  TNF-­‐α	  are	  the	  most	  important	  stimuli	  that	  induce	  monocytes	  and	  macrophages	  to	  generate	  IL-­‐8(24).	  It	  is	  though	  that	  IL-­‐8	   plays	   more	   a	   role	   of	   chemotactic	   agonist	   rather	   than	   a	   cytokine.	   It	   is	   the	   main	   tissue-­‐derived	  chemoattractants	   for	   neutrophils	   but	   also	   for	   other	   granulocytes.	   	   Moreover,	   IL-­‐8	   dependant	   surface	  membrane	   remodeling	   during	   exocytosis	   leads	   to	   the	   expression	   of	   adhesion	   molecules	   such	   as	  CD11b/CD18,	   CD11c/CD18	   and	   complement	   receptor	   type	   1(25,26)	   that	   upregulate	   neutrophils	   to	  adhere	  to	  endothelial	  cells	  and	  to	  the	  extracellular	  matrix.	  Regarding	  IL-­‐8	  function	  it	  is	  not	  surprising	  that	  its	  concentration	  is	  increased	  in	  both	  sera	  and	  pancreatic	  tissues	  of	  patients	  suffering	  of	  type	  2	  AIP	  since	  the	   principal	   characteristic	   of	   type	   2	   AIP	   is	   the	   presence	   of	   important	   neutrophils	   in	   the	   pancreatic	  parenchyma.	  	  Interestingly,	  we	  failed	  to	  find	  increase	  in	  IL-­‐13	  and	  IL-­‐10	  expressions	  in	  the	  pancreatic	  tissues	  of	  patients	  suffering	  of	  AIP	  as	  Zen	  et	  al.	  reported(6).	  Indeed,	  they	  speculated	  that	  IL-­‐10	  may	  a	  have	  a	  potential	  role	  in	  directing	  B	  cells	  to	  produce	  IgG4	  and	  then	  be	  responsible	  of	  the	  elevation	  of	  serum	  IgG4	  concentrations	  and	   IgG4-­‐positive	   plasma	   cell	   infiltration.	   Because,	   AIP	   patient	   has	   also	   increase	   serum	   IgE	   level	   and	  sometimes	  eosinophilic	  infiltration	  (more	  in	  type	  2	  AIP	  for	  this	  latter)	  it	  was	  though	  that	  increased	  IL-­‐13	  might	  have	  also	  a	  role	  in	  the	  pathogenesis	  of	  AIP.	  	  	  
Conclusion:	  Autoimmune	  pancreatitis	  is	  a	  newly	  described	  form	  of	  pancreatitis.	  Two	  different	  subtypes	  with	  distinct	  clinical	   presentation	   have	   been	   reported	   including	   differences	   in	   geographic	   distribution,	   age	   of	  appearance,	  sex	  ratio,	  histological	  and	  immunological	  features	  and	  rate	  of	  relapse	  after	  steroid	  treatment.	  As	   both	   subtypes	   have	   been	   recently	   individualized	   few	   studies	   compared	   both	   types	   in	   term	   of	  pathogenic	   mechanism.	   Furthermore,	   diagnosis	   of	   AIP	   remains	   still	   a	   challenge	   and	   discrimination	  between	  both	  subtypes	  is	  only	  possible	  on	  histological	  specimen.	  For	  these	  reasons,	  we	  proposed	  here	  to	  assess	  cytokine	  expression	  in	  both	  type	  1	  and	  type	  2	  AIP.	  These	  two	  latter	  groups	  were	  compared	  to	  PDAC	  and	  CP,	  both	  difficult	  differential	  diagnosis	  of	  AIP.	  	  Mainly,	   we	   showed	   that	   interleukin-­‐8	   (IL-­‐8),	   macrophage	   inflammatory	   protein-­‐1	   beta	   (MIP-­‐1b)	   and	  monocyte	  chemotactic	  protein-­‐1	  (MCP-­‐1)	  are	  significantly	  more	  expressed	  in	  type	  2	  AIP	  than	  type	  1	  AIP.	  MIP-­‐1b	  and	  MCP-­‐1	  are	  produced	  by	  macrophages	  and	  have	  a	  crucial	  role	  for	  immune	  responses	  towards	  infection	   and	   inflammation.	   IL-­‐8,	   MCP-­‐1	   and	   MIP-­‐1b	   are	   pro-­‐inflammatory	   cytokines	   that	   induce	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infiltration	   and	   activation	   of	   leukocytes-­‐mainly	   neutrophils	   into	   the	   sites	   of	   inflammation	   of	   pancreas.	  This	  results	  into	  a	  continuous	  activation	  and	  amplification	  of	  the	  cytokine	  cascade	  that	  might	  be	  the	  origin	  of	   the	   specific	   histological	   characteristic	   of	   type	   2	   AIP	   that	   is	   the	   invasion	   and	   destruction	   of	   the	  pancreatic	  duct	  epithelium	  by	  granulocytes	  (GELs)	  mainly	  neutrophils.	  	  These	  three	  cytokines	  may	  help	  to	  distinguish	  both	  types	  of	  AIP.	  However,	  further	  studies	  are	  required	  to	  explain	  the	  role	  of	  activated	  macrophages	  in	  type	  2	  AIP	  and	  the	  origin	  of	  this	  activation.	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Annexes:	  
	  
Table	  8:	  Mean	  cytokine	  concentrations	  in	  sera	  (pg/ml),	  SE:	  standard	  error,	  n:	  number	  of	  observation	  in	  the	  
operational	  measurement	  range	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Table	  9:	  Mean	  cytokine	  concentrations	  in	  pancreatic	  tissues	  (pg/ml),	  SE:	  standard	  error,	  n:	  number	  of	  
observation	  in	  the	  operational	  measurement	  range
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